Cognitive function following SARS-CoV-2 infection in a population-representative Canadian sample.
Brain
COVID-19
Cognition
Delay discounting
Executive function
OFC
SARS-CoV-2
Journal
Brain, behavior, & immunity - health
ISSN: 2666-3546
Titre abrégé: Brain Behav Immun Health
Pays: United States
ID NLM: 101759062
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
16
01
2022
revised:
12
03
2022
accepted:
12
03
2022
entrez:
28
3
2022
pubmed:
29
3
2022
medline:
29
3
2022
Statut:
ppublish
Résumé
SARS-CoV-2 infection is believed to adversely affect the brain, but the degree of impact on socially relevant cognitive functioning and decision-making is not well-studied, particularly among those less vulnerable to age-related mortality. The current study sought to determine whether infection status and COVID-19 symptom severity are associated with cognitive dysfunction among young and middled-aged adults in the general population, using self-reported lapses in executive control and a standardized decision-making task. The survey sample comprised 1958 adults with a mean age of 37 years ( Young and middle-aged adults with a positive SARS-CoV-2 infection history reported a significantly higher number of cognitive dysfunction symptoms ( Positive SARS-CoV-2 infection history and moderate or higher COVID-19 symptom severity are associated with significant symptoms of cognitive dysfunction and amplified delay discounting among young and middle-aged adults with no history of medically induced coma.
Sections du résumé
Background
UNASSIGNED
SARS-CoV-2 infection is believed to adversely affect the brain, but the degree of impact on socially relevant cognitive functioning and decision-making is not well-studied, particularly among those less vulnerable to age-related mortality. The current study sought to determine whether infection status and COVID-19 symptom severity are associated with cognitive dysfunction among young and middled-aged adults in the general population, using self-reported lapses in executive control and a standardized decision-making task.
Method
UNASSIGNED
The survey sample comprised 1958 adults with a mean age of 37 years (
Results
UNASSIGNED
Young and middle-aged adults with a positive SARS-CoV-2 infection history reported a significantly higher number of cognitive dysfunction symptoms (
Conclusions
UNASSIGNED
Positive SARS-CoV-2 infection history and moderate or higher COVID-19 symptom severity are associated with significant symptoms of cognitive dysfunction and amplified delay discounting among young and middle-aged adults with no history of medically induced coma.
Identifiants
pubmed: 35340304
doi: 10.1016/j.bbih.2022.100454
pii: S2666-3546(22)00044-8
pmc: PMC8934755
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100454Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Lancet Psychiatry. 2021 May;8(5):416-427
pubmed: 33836148
Clin Infect Dis. 2014 Mar;58(6):775-84
pubmed: 24352349
Laryngoscope. 2020 Jul;130(7):1787
pubmed: 32237238
J Affect Disord. 2020 Oct 1;275:112-118
pubmed: 32658812
J Neurosci. 2010 Dec 8;30(49):16429-36
pubmed: 21147982
Nature. 2022 Mar 7;:
pubmed: 35255491
JAMA. 2020 Oct 13;324(14):1381-1383
pubmed: 32965460
Science. 2004 Oct 15;306(5695):503-7
pubmed: 15486304
Neuroimage. 2015 Oct 15;120:104-13
pubmed: 26163803
N Engl J Med. 2000 Mar 2;342(9):635-45
pubmed: 10699164
J Affect Disord. 2020 Dec 1;277:55-64
pubmed: 32799105
EClinicalMedicine. 2021 Sep;39:101044
pubmed: 34316551
Cereb Cortex. 2006 Jan;16(1):106-14
pubmed: 15829733
JAMA Neurol. 2021 Jun 1;78(6):760-762
pubmed: 33576767
Prog Neurobiol. 2004 Apr;72(5):341-72
pubmed: 15157726
JAMA Psychiatry. 2021 Jun 1;78(6):682-683
pubmed: 33769431
Circ Res. 2020 Jul 31;127(4):571-587
pubmed: 32586214
Int J Infect Dis. 2022 Mar;116:38-42
pubmed: 34971823
Arch Neurol. 2008 May;65(5):596-600
pubmed: 18474734
World Psychiatry. 2021 Feb;20(1):52-53
pubmed: 33432769
BMJ. 2021 Dec 23;375:n3144
pubmed: 34949600
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1049-1057
pubmed: 32790653
Exp Clin Psychopharmacol. 2014 Jun;22(3):222-8
pubmed: 24708144
JAMA Netw Open. 2021 Oct 1;4(10):e2130645
pubmed: 34677597
J Pers Soc Psychol. 2011 Jan;100(1):182-95
pubmed: 21219079
Nat Rev Neurol. 2021 Feb;17(2):65-66
pubmed: 33414554
Brain Behav Immun Health. 2020 Dec;9:100163
pubmed: 33111132
Lancet Infect Dis. 2016 Dec;16(12):1356-1363
pubmed: 27641777
J Clin Neurol. 2017 Jul;13(3):227-233
pubmed: 28748673
Neuropsychopharmacology. 2021 Dec;46(13):2235-2240
pubmed: 33589778
Addiction. 2001 Jan;96(1):73-86
pubmed: 11177521
Mol Neurodegener. 2021 Jul 19;16(1):48
pubmed: 34281568
BMC Health Serv Res. 2020 Dec 20;20(1):1144
pubmed: 33342437
Psychol Med. 2020 Nov 13;:1-10
pubmed: 33183370
Curr Biol. 2016 Oct 10;26(19):2625-2628
pubmed: 27593380
Psychosom Med. 2021 May 1;83(4):309-321
pubmed: 33790201
Brain Behav Immun Health. 2022 Feb;19:100399
pubmed: 34870247
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288